Paul J. Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Paul J. Smith has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Abigail C. Jackson
Department of Chemistry Duke University Durham NC 27708 USA
1 shared publication Adnan Baker‐Agha
Department of Chemistry and Biochemistry University of Maryland Baltimore County Baltimore MD 21250 USA
1 shared publicationAmy Jo Glemza
Departments of Chemical and Biochemical Engineering and Chemistry and Biochemistry, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, Maryland 21250, and Center for Agricultural Biotechnology, 5115 Plant Sciences Building, University of Maryland, College Park, Maryland 20742-4450
1 shared publicationBrian J. Brune
Departments of Chemical and Biochemical Engineering and Chemistry and Biochemistry, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, Maryland 21250, and Center for Agricultural Biotechnology, 5115 Plant Sciences Building, University of Maryland, College Park, Maryland 20742-4450
1 shared publicationCraig S. Wilcox
1 shared publicationDaniel C. Talley
Department of Chemistry and Biochemistry University of Maryland Baltimore County Baltimore MD 21250 USA
1 shared publication
Latest Publications
- 19 November 2020
- Published by Wiley in ChemMedChem
- Vol. 16 (4) , 654-661
Benzimidazole and Benzoxazole Zinc Chelators as Inhibitors of Metallo‐β‐Lactamase NDM‐1
Bacterial expression of β‐lactamases, which hydrolyze β‐lactam antibiotics, contributes to the growing threat of antibacterial drug resistance. Metallo‐β‐lactamases, such as NDM‐1, use catalytic zinc ions in their active sites and hydrolyze nearly all clinically available β‐lactam antibiotics. Inhibitors of metallo‐β‐lactamases are urgently needed to overcome this resistance mechanism. Zinc‐binding compounds are promising leads for inhibitor development, as many NDM‐1 inhibitors contain zinc‐binding pharmacophores. Here, we evaluated 13 chelating agents containing benzimidazole and benzoxazole scaffolds as NDM‐1 inhibitors. Six of the compounds showed potent inhibitory activity with IC50 values as low as 0.38 μM, and several compounds restored the meropenem susceptibility of NDM‐1‐expressing E. coli. Spectroscopic and docking studies suggest ternary complex formation as the mechanism of inhibition, making these compounds promising for development as NDM‐1 inhibitors.
- 19 November 2020
- Published by Wiley in ChemMedChem
- Vol. 16 (4) , 654-661
Benzimidazole and Benzoxazole Zinc Chelators as Inhibitors of Metallo‐β‐Lactamase NDM‐1
Bacterial expression of β‐lactamases, which hydrolyze β‐lactam antibiotics, contributes to the growing threat of antibacterial drug resistance. Metallo‐β‐lactamases, such as NDM‐1, use catalytic zinc ions in their active sites and hydrolyze nearly all clinically available β‐lactam antibiotics. Inhibitors of metallo‐β‐lactamases are urgently needed to overcome this resistance mechanism. Zinc‐binding compounds are promising leads for inhibitor development, as many NDM‐1 inhibitors contain zinc‐binding pharmacophores. Here, we evaluated 13 chelating agents containing benzimidazole and benzoxazole scaffolds as NDM‐1 inhibitors. Six of the compounds showed potent inhibitory activity with IC50 values as low as 0.38 μM, and several compounds restored the meropenem susceptibility of NDM‐1‐expressing E. coli. Spectroscopic and docking studies suggest ternary complex formation as the mechanism of inhibition, making these compounds promising for development as NDM‐1 inhibitors.
- 8 April 2009
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 19 (4) , 433-460
Patents related to therapeutic activation of KATPand K2Ppotassium channels for neuroprotection: ischemic/hypoxic/anoxic injury and general anesthetics
Background: Mechanisms of neuroprotection encompass energy deficits in brain arising from insufficient oxygen and glucose levels following respiratory failure; ischemia or stroke, which produce metabolic stresses that lead to unconsciousness and seizures; and the effects of general anesthetics. Foremost among those K+ channels viewed as important for neuroprotection are ATP-sensitive (KATP) channels, which belong to the family of inwardly rectifying K+ channels (Kir) and contain a sulfonylurea subunit (SUR1 or SUR2) combined with either Kir6.1 (KCNJ8) or Kir6.2 (KCNJ11) channel pore-forming α-subunits, and various members of the tandem two-pore or background (K2P) K+ channel family, including K2P1.1 (KCNK1 or TWIK1), K2P2.1 (KCNK2 or TREK/TREK1), K2P3.1 (KCNK3 or TASK), K2P4.1 (KCNK4 or TRAAK), and K2P10.1 (KCNK10 or TREK2). Objectives: This review covers patents and patent applications related to inventions of therapeutics, compound screening methods and diagnostics, including KATP channel openers and blockers, as well as KATP and K2P nucleic/amino acid sequences and proteins, vectors, transformed cells and transgenic animals. Although the focus of this patent review is on brain and neuroprotection, patents covering inventions of KATP channel openers for cardioprotection, diabetes mellitus and obesity, where relevant, are addressed. Results/conclusions: Overall, an important emerging therapeutic mechanism underlying neuroprotection is activation/opening of KATP and K2P channels. To this end substantial progress has been made in identifying and patenting agents that target KATP channels. However, current K2P channels patents encompass compound screening and diagnostics methodo-logies, reflecting an earlier ‘discovery’ stage (target identification/validation) than KATP in the drug development pipeline; this reveals a wide-open field for the discovery and development of K2P-targeting compounds.
- 8 April 2009
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 19 (4) , 433-460
Patents related to therapeutic activation of KATPand K2Ppotassium channels for neuroprotection: ischemic/hypoxic/anoxic injury and general anesthetics
Background: Mechanisms of neuroprotection encompass energy deficits in brain arising from insufficient oxygen and glucose levels following respiratory failure; ischemia or stroke, which produce metabolic stresses that lead to unconsciousness and seizures; and the effects of general anesthetics. Foremost among those K+ channels viewed as important for neuroprotection are ATP-sensitive (KATP) channels, which belong to the family of inwardly rectifying K+ channels (Kir) and contain a sulfonylurea subunit (SUR1 or SUR2) combined with either Kir6.1 (KCNJ8) or Kir6.2 (KCNJ11) channel pore-forming α-subunits, and various members of the tandem two-pore or background (K2P) K+ channel family, including K2P1.1 (KCNK1 or TWIK1), K2P2.1 (KCNK2 or TREK/TREK1), K2P3.1 (KCNK3 or TASK), K2P4.1 (KCNK4 or TRAAK), and K2P10.1 (KCNK10 or TREK2). Objectives: This review covers patents and patent applications related to inventions of therapeutics, compound screening methods and diagnostics, including KATP channel openers and blockers, as well as KATP and K2P nucleic/amino acid sequences and proteins, vectors, transformed cells and transgenic animals. Although the focus of this patent review is on brain and neuroprotection, patents covering inventions of KATP channel openers for cardioprotection, diabetes mellitus and obesity, where relevant, are addressed. Results/conclusions: Overall, an important emerging therapeutic mechanism underlying neuroprotection is activation/opening of KATP and K2P channels. To this end substantial progress has been made in identifying and patenting agents that target KATP channels. However, current K2P channels patents encompass compound screening and diagnostics methodo-logies, reflecting an earlier ‘discovery’ stage (target identification/validation) than KATP in the drug development pipeline; this reveals a wide-open field for the discovery and development of K2P-targeting compounds.
- 3 August 2000
- Published by American Chemical Society (ACS) in Industrial & Engineering Chemistry Research
- Vol. 39 (9) , 3347-3355
Potential Approach for Fractionating Oxygenated Aromatic Compounds from Renewable Resources
- 3 August 2000
- Published by American Chemical Society (ACS) in Industrial & Engineering Chemistry Research
- Vol. 39 (9) , 3347-3355
Potential Approach for Fractionating Oxygenated Aromatic Compounds from Renewable Resources
- 1 October 1990
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 55 (22) , 5675-5678
The chemistry of synthetic receptors and functional group arrays. 13. The intramolecular salt effect
- 1 October 1990
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 55 (22) , 5675-5678
The chemistry of synthetic receptors and functional group arrays. 13. The intramolecular salt effect